In NSCLC patients treated with anti-PD-1 therapy, responders exhibit increased proliferation of T PD-1+CD8+cells with an effector phenotype (HLA-DR+ CD38+ BCL-2low) and elevated expression of CD28 (Table 5) [110]. Here, CD8A is linked to non-small cell lung carcinoma.